Beneficial effects of propionyl L-carnitine therapy in diabetic cardiomyopathy

In this review, the beneficial effects of metabolic therapy with propionyl L-carnitine (PPLC) on cardiovascular complications during the development of diabetic cardiomyopathy was evaluated. Since metabolic abnormalities due to mitochondrial dysfunction are invariably associated with deficiency of c...

Full description

Saved in:
Bibliographic Details
Main Authors: Kaur Khushman, Kirshenbaum Lorrie, Tappia Paramjit S, Dhalla Naranjan S
Format: Article
Language:English
Published: Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine 2025-01-01
Series:Scripta Medica
Subjects:
Online Access:https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2025/2490-33292503557K.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849252380342747136
author Kaur Khushman
Kirshenbaum Lorrie
Tappia Paramjit S
Dhalla Naranjan S
author_facet Kaur Khushman
Kirshenbaum Lorrie
Tappia Paramjit S
Dhalla Naranjan S
author_sort Kaur Khushman
collection DOAJ
description In this review, the beneficial effects of metabolic therapy with propionyl L-carnitine (PPLC) on cardiovascular complications during the development of diabetic cardiomyopathy was evaluated. Since metabolic abnormalities due to mitochondrial dysfunction are invariably associated with deficiency of carnitine, accumulation of toxic long-chain derivatives of fatty acids and development of oxidative stress in the heart, it appears that the effects of PPLC therapy are related to the attenuation of these derangements. Particularly, the beneficial effects of PPLC therapy in improving cardiac function in chronic diabetes were associated with attenuation of increase in sarcolemmal Ca2+-binding and Ca2+-ecto ATPase activities. Furthermore, depressed sarcolemmal Na+-K+ ATPase and Na+-dependent Ca2+-uptake as well as sarcoplasmic reticulum Ca2+-pump activities in diabetic hearts were attenuated by PPLC therapy. These actions of PPLC therapy were accompanied by improvement in mitochondrial oxidative phosphorylation and attenuation of changes in the high energy phosphate stores in the diabetic heart. Since incubation of sarcolemma with PPLC was found to reduce the inhibitory actions of palmitoyl L-carnitine on Na+-K+ ATPases and Na+-dependent Ca2+-uptake, it is suggested that PPLC therapy may attenuate cardiac abnormalities by antagonising the deleterious actions of accumulated longchain lipids in diabetic cardiomyopathy.
format Article
id doaj-art-5a7ca2130e264b0f9f9abf6b025d1d4a
institution Kabale University
issn 2490-3329
2303-7954
language English
publishDate 2025-01-01
publisher Medical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of Medicine
record_format Article
series Scripta Medica
spelling doaj-art-5a7ca2130e264b0f9f9abf6b025d1d4a2025-08-20T03:56:38ZengMedical Society of the Republic of Srpska, Banja Luka, University of Banja Luka. Faculty of MedicineScripta Medica2490-33292303-79542025-01-0156355756510.5937/scriptamed56-595992490-33292503557KBeneficial effects of propionyl L-carnitine therapy in diabetic cardiomyopathyKaur Khushman0https://orcid.org/0009-0002-7013-3231Kirshenbaum Lorrie1https://orcid.org/0000-0002-9617-5803Tappia Paramjit S2https://orcid.org/0000-0001-8307-2760Dhalla Naranjan S3https://orcid.org/0000-0002-4894-4727University of Manitoba, Max Rady College of Medicine, St. Boniface Hospital Albrechtsen Research Centre, Department of Physiology and Pathophysiology, Institute of Cardiovascular Sciences, Winnipeg, CanadaUniversity of Manitoba, Max Rady College of Medicine, St. Boniface Hospital Albrechtsen Research Centre, Department of Physiology and Pathophysiology, Institute of Cardiovascular Sciences, Winnipeg, CanadaSt. Boniface Hospital, Asper Clinical Research Institute, Winnipeg, CanadaUniversity of Manitoba, Max Rady College of Medicine, St. Boniface Hospital Albrechtsen Research Centre, Department of Physiology and Pathophysiology, Institute of Cardiovascular Sciences, Winnipeg, CanadaIn this review, the beneficial effects of metabolic therapy with propionyl L-carnitine (PPLC) on cardiovascular complications during the development of diabetic cardiomyopathy was evaluated. Since metabolic abnormalities due to mitochondrial dysfunction are invariably associated with deficiency of carnitine, accumulation of toxic long-chain derivatives of fatty acids and development of oxidative stress in the heart, it appears that the effects of PPLC therapy are related to the attenuation of these derangements. Particularly, the beneficial effects of PPLC therapy in improving cardiac function in chronic diabetes were associated with attenuation of increase in sarcolemmal Ca2+-binding and Ca2+-ecto ATPase activities. Furthermore, depressed sarcolemmal Na+-K+ ATPase and Na+-dependent Ca2+-uptake as well as sarcoplasmic reticulum Ca2+-pump activities in diabetic hearts were attenuated by PPLC therapy. These actions of PPLC therapy were accompanied by improvement in mitochondrial oxidative phosphorylation and attenuation of changes in the high energy phosphate stores in the diabetic heart. Since incubation of sarcolemma with PPLC was found to reduce the inhibitory actions of palmitoyl L-carnitine on Na+-K+ ATPases and Na+-dependent Ca2+-uptake, it is suggested that PPLC therapy may attenuate cardiac abnormalities by antagonising the deleterious actions of accumulated longchain lipids in diabetic cardiomyopathy.https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2025/2490-33292503557K.pdfdiabetic cardiomyopathiespropionyl l-carnitinepalmitoyl l-carnitineoxidative stresssarcolemmasarcoplasmic reticulummitochondria
spellingShingle Kaur Khushman
Kirshenbaum Lorrie
Tappia Paramjit S
Dhalla Naranjan S
Beneficial effects of propionyl L-carnitine therapy in diabetic cardiomyopathy
Scripta Medica
diabetic cardiomyopathies
propionyl l-carnitine
palmitoyl l-carnitine
oxidative stress
sarcolemma
sarcoplasmic reticulum
mitochondria
title Beneficial effects of propionyl L-carnitine therapy in diabetic cardiomyopathy
title_full Beneficial effects of propionyl L-carnitine therapy in diabetic cardiomyopathy
title_fullStr Beneficial effects of propionyl L-carnitine therapy in diabetic cardiomyopathy
title_full_unstemmed Beneficial effects of propionyl L-carnitine therapy in diabetic cardiomyopathy
title_short Beneficial effects of propionyl L-carnitine therapy in diabetic cardiomyopathy
title_sort beneficial effects of propionyl l carnitine therapy in diabetic cardiomyopathy
topic diabetic cardiomyopathies
propionyl l-carnitine
palmitoyl l-carnitine
oxidative stress
sarcolemma
sarcoplasmic reticulum
mitochondria
url https://scindeks-clanci.ceon.rs/data/pdf/2490-3329/2025/2490-33292503557K.pdf
work_keys_str_mv AT kaurkhushman beneficialeffectsofpropionyllcarnitinetherapyindiabeticcardiomyopathy
AT kirshenbaumlorrie beneficialeffectsofpropionyllcarnitinetherapyindiabeticcardiomyopathy
AT tappiaparamjits beneficialeffectsofpropionyllcarnitinetherapyindiabeticcardiomyopathy
AT dhallanaranjans beneficialeffectsofpropionyllcarnitinetherapyindiabeticcardiomyopathy